Myeloma Round Table Beth Faiman MSN, APRN-BC, AOCN Nurse Practitioner, Cleveland Clinic Pre-Doctoral Fellow, Case Western Reserve.

Slides:



Advertisements
Similar presentations
Multiple Myeloma By Dr Sameh Shamaa. Multiple Myeloma Epidemiology: 1% Of all malignant diseases. Annual incidence: 3-4/ Age: - Median age: 65y.
Advertisements

Multiple Myeloma Serena Ezzeddine Morning Report May 30, 2009.
Heather D. Mannuel, MD, MBA March 12, 2008
1 Acute Renal Failure At the end of this self study the participant will: Differentiate between pre, intra and post renal failure Describe dialysis modes:
Renal replacement therapy - indications. S. Zmonarski.
Nursing 210 Fluid and Cells Nursing management of patients with hematologic dysfunction Laurie Brown RN, MSN, MPA-HA, CCRN.
Rick Allen.  A malignant proliferation of plasma cells derived from a single clone, with multifocal involvement of the skeleton.
PLASMA CELL DYSCRASIAS Monoclonal gammopathy of uncertain significance (MGUS)  Idiopathic  Associated with other diseases (autoimmune, infectious, non-heme.
Staff Oncologist, Mayo Clinic Arizona
IMMUNE THROMBOCYTOPENIA Cathy Payne MSN, ACNP-BC Hematology/Oncology Nurse Practitioner Ironwood Cancer and Research Centers.
Why did vitamin B12 deficiency respond to plasmapheresis?
Drugs Used in the Treatment of Multiple Myeloma Myeloma Canada National Conference 2011-September-24 Toronto, Ontario Carlo De Angelis, RPh, PharmD Clinical.
Objectives To introduce the terminology used in describing the plasma cells neoplasm. To explain the physiology of the normal cells & the pathological.
The Many Faces of Hydroxyurea Soheir Adam, MD. Sickle Cell Disease The commonest genetic disorder in the US Affects about 75,000 individuals Single genetic.
THROMBOCYTOPENIA - reduced platelet count -. First of all.. what are platelets? Platelets: tiny cells that circulate in the blood and whose function is.
Autoimmune Idiopathic Thrombocytopenic Purpura (ITP) Nicola Davis.
Waldenstrom’s Macroglobulinemia
NURSING CARE OF THE CHILD WITH A HEMATOLOGIC ALTERATION.
Cast Nephropathy & Plasmapheresis Alicia Notkin February 6, 2008.
Multiple Myeloma: Practice Patterns of Oncology Nurses
Understanding Your Blood Work
Leukemia & Lymphoma Keith Rischer, RN, MA, CEN. Leukemia Patho Loss of regulation in cell division, causes proliferation of malignant leukocytes Classification.
Cancer Among Native Americans in Arizona and New Mexico Data Provided by Arizona Cancer Registry at the Arizona Department of Health Services and the New.
Multiple Myeloma Definition:
Multiple Myeloma Presented by: Mike Lynch Mike Lynch.
Aswad H. Al.Obeidy FICMS, FICMS GE&Hep Kirkuk General Hospital
1 Parathyroid Gland Dysfunction Excela Health School of Anesthesia.
Multiple Myeloma Definition: B-cell malignancy characterised by abnormal proliferation of plasma cells able to produce a monoclonal immunoglobulin (M protein)
Multiple Myeloma Definition:
Renal Disease Normal Anatomy andPhysiology. Renal: Normal Anatomy 1. Renal artery and vein: 25% of blood volume passes through the kidney / minute 2.
The Importance of Survivorship in Multiple Myeloma Beth Faiman MSN, APRN, BC, AOCN® Nurse Practitioner, Taussig Cancer Institute, Cleveland Clinic Pre-Doctoral.
The Importance of Survivorship in Multiple Myeloma.
ONS Update: New Approaches to Renal Insufficiency Beth Faiman RN, MSN, APRN-BC, AOCN Nurse Practitioner, Cleveland ClinicTaussig Cancer Institute Pre-Doctoral.
Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney Sophina Hissaund FY2.
Treatment Multiple Myeloma. Symptomatic/progressive myeloma: Systemic therapy - to control progression of myeloma Supportive care - to prevent serious.
LYMPHOPROLIFERATIVE DISORDERS
Multiple Myeloma Morning Report July 21, 2009 Lindsay Kruska.
Justin A. Crocker.  1 of the monoclonal gammopathies  Neoplastic proliferation of immunoglobulin producing plasma cells (single clone), often resulting.
Dr. Aya M. Serry Renal Failure Renal failure is defined as a significant loss of renal function in both kidneys to the point where less than 10.
Plasma cell dyscrasias. Multiple Myeloma By Dr. Muna A. Kashmool.
Chapter 37 Chronic Kidney Disease: The New Epidemic
Myeloma and the Kidney Ryan Sanford How Often is the Kidney Involved Symptomatic MM: CRAB – hyperCalcemia – Renal dysfunction – Anemia – Bone.
PHARMACOLOGIC MANAGEMENT. SYMPTOMATIC THERAPY Includes therapies for constipation, spinal instability, pain, and psychological and social distress Constipation.
J Winterbottom 2005 Chronic Renal Failure (CRF) (End stage renal disease ) (ESRD)
M. Multiple Myeloma Malignant proliferation of plasma cells. Malignant proliferation of plasma cells. Normal plasma cell form Ig which contain heavy and.
Multiple Myeloma March 13, 2012 Suzanne R. Fanning, DO Greenville Health System.
Presentation by JoAnn Czech RN/CDS St. Cloud Hospital.
Multiple Myeloma: Is it now a curable disease?
Department of Nephrology Hypercalcemia R4 Song Se-bin.
Renal failure  It implies destruction of nephrons and failure of the kidney to maintain hemostasis (failure to excrete waste products or regulate water.
Management: Spinal Cord Compression
Case Study Multiple Myeloma.
Prepared by : IBRAHEEM NIDAL ABU ATWAN SAEED YEHYA HAMMODA
Presented By Dr / Said Said Elshama
MLAB Hematology Keri Brophy-Martinez
Lenograstim Chemical Formula : C840-H1330-N222-O242-S8
Dr WAQAR ASST. PROFESSOR INTERNAL MEDICINE
MLAB Hematology Fall 2007 Keri Brophy-Martinez
Kidney and Drugs.
Diuretics, Kidney Diseases Urine R&M
A young patient with multiple myeloma
Multiple myeloma (MM) & related disorders
IMMUNE THROMBOCYTOPENIC PURPURA MBBSPPT.COM
Myeloma: Symptoms to diagnosis Can we do better?
Volume 73, Issue 11, Pages (June 2008)
PARAPRTEINAEMIA and MULTIPLE MYELOMA
Myeloma 101 and Standards of Care for Myeloma
Renal Function and Myeloma Therapeutics
Red Blood Cell Disorders
Presentation transcript:

Myeloma Round Table Beth Faiman MSN, APRN-BC, AOCN Nurse Practitioner, Cleveland Clinic Pre-Doctoral Fellow, Case Western Reserve

Hematologic events: Neutropenia and Thrombocytopenia Neutropenia – Functional neutrophils are critical to the immune system – Neutropenia can occur from treatment or the disease itself – Educate signs and symptoms of infection Risk is primarily during times of low WBC or treatment with agents that lower immune function Miceli et al, 2008.

Hematologic events: Neutropenia and Thrombocytopenia Prophylactic antibiotic usage for neutropenia is controversial – Generally not done except during high-dose therapy (transplant setting) or if planned prolonged neutropenia in high-risk patients Treatment – Colony-stimulating factors increase WBC Sargramostim Filgrastim Peg-filgrastim – Treat the myeloma itself if disease related Miceli et al, 2008.

Thrombocytopenia Low blood platelets May be a result of treatment of disease itself (marrow crowded out by atypical plasma cells Signs: – Bleeding – Purpura – Petechiae Diagnosis – Low Platelet count (normal ) Treatment – Watchful waiting – Treat disease – Platelet transfusion – Hold anti-myeloma therapy if indicated Bortezomib, lenalidomide, etc. UTI = urinary tract infection; IVIG = intravenous immunoglobulin; PCP = pneumocystis pneumonia. Paradisi et al, 2001; Kollef, 2008; Gooskens et al, 2009; Ferguson et al, 2009; Pneumovax ® prescribing information, 2009; Zostavax ® prescribing information, 2009.

Hypercalcemia and Bone Loss Hypercalcemia in 15% of patients – Increased calcium levels, dehydration can precipitate renal failure – Treat with pamidronate, hydration, treat the disease Pathobiology: Malignant cells produce osteoclast- activating factors that destroy bone cells – Osteoclast stimulation leads to extensive osteolysis, severe bone pain, and pathologic fractures – Spinal cord compression – Plasmacytoma with significant bone destruction Most visible aspect of myeloma – 80% of patients develop bone disease Roodman, 2008.

Hypercalcemia of Malignancy Symptoms – Altered LOC, constipation, coma Diagnosis: Confirm by measuring CSC mg/dL (4.0 – serum ALB g/dL) Serum calcium mg/dL Example Calcium = 11.0 mg/dL ALB = 3.0 mg/dL = 1.0 a)Multiply (1.0) by 0.8, and add to the calcium of 11.0 CSC = 11.8 mg/dL LOC = level of consciousness; CSC = corrected serum calcium. Payne, 2004.

Renal Dysfunction Bence-Jones proteinuria: Incidence ~ 70% – Light chain Igs can precipitate and damage renal cells – Free light chains filtered in the nephron’s glomerulus, then absorbed and metabolized by proximal tubular cells – Heavy and light chains can cause renal tubular damage – sFLC assay more reliable than urine – ATN secondary to NSAIDS, dehydration, nephrotoxic agents (CT dyes) – Supportive therapy Hydration, correct underlying cause with treatment Avoid IV contrast and nephrotoxic agents (IV dyes, NSAIDS) Plasmapheresis, dialysis ATN = acute tubular necrosis; NSAIDS = non-steroidal anti-anflammatory drugs. Rajkumar et al, 2001; Dimopoulos et al, 2008; Botchler et al, 2008; Wong et al, 2007.